NXI therapeutics focuses on the research and development of a new generation of selective immunosuppressive drugs for autoimmune diseases and transplantations - with objectives of high efficacy, good safety without adverse effects as seen with conventional immunosuppressants.
Company Details
- Employees
- 5
- Founded
- 2021
- Address
- Spitalstrasse 41, 10.094,switzerland
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- HQ
- Basel, Basel Stadt
Nxi Therapeutics Ag Questions
Nxi Therapeutics Ag's website is https://www.nxitherapeutics.com/about-nxitherapeutics
Nxi Therapeutics Ag's LinkedIn profile is https://ch.linkedin.com/company/nxitherapeutics
Nxi Therapeutics Ag has
5 employees.
View email and phone details for 5
employees at Nxi Therapeutics Ag.
Nxi Therapeutics Ag's industry is
Biotechnology Research
Nxi Therapeutics Ag's top competitors are
Allegria Therapeutics,
Rege Nephro Co., Ltd.,
Aukera Therapeutics,
Synendos Therapeutics Ag,
Biospectal Sa,
Cellestia Biotech,
Clexbio,
Tandem Therapeutics,
Regenosca Sa,
Ymmunobio.
Nxi Therapeutics Ag's categories are Biotechnology Research
Nxi Therapeutics Ag's founding year is 2021
